Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05964829
Other study ID # CIONIC-06-001
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 4, 2023
Est. completion date June 2024

Study information

Verified date February 2024
Source Cionic, Inc.
Contact Douglas A Wajda, PhD
Phone 3308837149
Email d.a.wajda@csuohio.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research is to support the clinical value of the Cionic Neural Sleeve for individuals diagnosed with multiple sclerosis (MS).


Description:

The randomized within-participants crossover study aims to demonstrate the clinical impact of the Cionic Neural Sleeve for individuals diagnosed with MS. Physical measurements, performance-based tests, and questionnaire responses will be recorded. These include physical activity recorded by an Actigraph; in-person tests measuring disability, spasticity and balance; and questionnaires gauging perceived walking ability, quality of life, and physical and psychological impact of MS. All participants will be assigned a hip-worn Actigraph activity monitor, a Cionic Neural Sleeve on the most impacted leg, and prescribed a home-based intervention of 15 minutes of walking for 5 days a week for 12 weeks. The Actigraph will be worn for the duration of the 12-week walking intervention, while the Cionic Neural Sleeve will be worn for 6 weeks of the study. Participants will be randomized to one of two groups: A or B. Group A will wear the Actigraph and receive stimulation assisted walking from the Neural Sleeve (intervention), while group B will only wear the Actigraph while walking. After 6 weeks, participants in each group will cross over to the other group.


Recruitment information / eligibility

Status Recruiting
Enrollment 6
Est. completion date June 2024
Est. primary completion date May 2024
Accepts healthy volunteers No
Gender All
Age group 22 Years to 75 Years
Eligibility Inclusion Criteria: - Persons with relapsing-remitting or progressive forms of MS between the ages of 22 and 75 - Ability to ambulate at least 15 minutes throughout the day for five days per week, with or without assistive device - Adequate cognitive and communicative function as assessed via Telephone Interview for Cognitive Status (TICS) to identify persons with dementia - Able to tolerate the Neural Sleeve device for up to 8 hours per day - T25FWT time between 8 and 45 seconds - No recent change in medication or recent exacerbation of symptoms over the last 60 days - Patient-determined Disease Steps score between 3 and 5 or EDSS score between 4 and 6.5 Exclusion Criteria: - Lower motor neuron disease or injury (e.g. peripheral neuropathy) that may impair response to stimulation - Absent sensation in the impacted or more impacted leg - Inadequate response to stimulation, defined by inability to achieve muscle contraction or unable to tolerate stimulation - Inability to ambulate with the sleeve in place of an ankle foot orthosis (AFO)/knee ankle foot orthosis (KAFO) if utilized - History of falls greater than once a week - No use of FES devices in the past year - Demand-type cardiac pacemaker or defibrillator - Malignant tumor in the impacted or more impacted leg - Existing thrombosis in the impacted or more impacted leg - Fracture or dislocation in the impacted or more impacted leg that could be adversely affected by motion from stimulation

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Cionic Neural Sleeve NS-100
The Cionic Neural Sleeve applies functional electrical stimulation as subjects walk to help contract appropriate muscles at appropriate times. The Cionic Neural Sleeve will be worn for 6 weeks.
Actigraph accelerometer
Physical activity will be recorded using an Actigraph accelerometer worn on the non-dominant hip.

Locations

Country Name City State
United States Cleveland State University Cleveland Ohio

Sponsors (1)

Lead Sponsor Collaborator
Cionic, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in Health-Related Quality of Life The Euroqol 5 Dimension 5 Level (EQ-5D-5L) questionnaire describes health profiles using different domains, measured by a 5-digit code. Single-digit numbers of the dimensions range from 1 to 5, with 1 indicative of no problem and 5 indicative of extreme problems in that domain. Day 0, Week 6, Week 12
Other Change in Impact of MS Multiple Sclerosis Impact Scale-29 (MSIS-29) questionnaire to measure the physical and psychological impact of MS, measured by score. Scores on the MSIS-29 are transformed into a score out of 100, with higher scores indicative of greater degree of disability. Day 0, Week 6, Week 12
Other Change in Perceived Fatigue Modified Fatigue Impact Scale (MFIS) survey to measure the effects of fatigue in physical, cognitive, and psychosocial functioning. MFIS score ranges from 0 to 84, with high scores indicative of a greater impact of fatigue on activities. Day 0, Week 6, Week 12
Other Change in Spasticity A trained clinician will administer the Modified Ashworth Scale (MAS) to assess for muscle tone and spasticity. Scores of the MAS range from 0 to 4, with high scores representative of increased muscle tone and spasticity. Week 1, Week 6, Week 12
Other Change in Lower Limb Strength Strength assessment of the ankle dorsiflexors, hamstrings, and quadriceps muscles using a handheld dynamometer in seated or laying in prone, measured in Newtons. Week 1, Week 6, Week 12
Other Change in Ankle Plantarflexor Strength Ankle plantarflexor strength will be measured by maximal repetitions of single leg heel raises. Week 1, Week 6, Week 12
Other Change in Lower Limb Range of Motion Range of motion of the ankle, knee, and hips will be assessed by a trained clinician using a handheld goniometer. Week 1, Week 6, Week 12
Other Change in Walking Endurance Measured via the 6-minute walk test, where subjects will walk as far as possible for 6 minutes, measured in meters. Week 1, Week 6, Week 12
Other Change in Balance Measured using force platform posturography in standing to quantify postural sway. There will be four 30-second trials with eyes open standing as still as possible. Week 1, Week 6, Week 12
Other Change in Blood Lipids Measured utilizing point of care analysis. The Cholestech LDX Analyzer provides accurate, actionable, and readily accessible results for point-of-care lipid profile and cholesterol testing, measured in milligrams per deciliter. Rapid, accurate results provide immediate awareness and identification of cardiovascular and diabetes health risks in only 5 minutes. Week 1, Week 6, Week 12
Other Change in Blood Glucose Measured utilizing point of care analysis. The Cholestech LDX Analyzer provides accurate, actionable, and readily accessible results for point-of-care glucose testing, measured in milligrams per deciliter. Rapid, accurate results provide immediate awareness and identification of cardiovascular and diabetes health risks in only 5 minutes. Week 1, Week 6, Week 12
Other Change in Incidence of Falls Measured using a self-reported fall diary and a survey, the Hopkins Fall Grading Scale, a 4-point scale to grade the nature and severity of a fall. Higher grades represent increased severity and impact of injurious falls. From enrollment to end of treatment at 12 weeks, post-intervention at Week 16
Other Change in Medication(s) and Dosage Measured by changes in dose intensities of prescribed medication(s). Day 0, Week 1, Week 6, Week 12, post-intervention at Week 16
Other Change in Pain Measured using the questionnaire, the Numeric Pain Rating Scale (NPRS), an 11-point numeric scale ranging from 0 to 10, with 0 being no pain and 10 being worst pain imaginable. Week 1, Week 6, Week 12
Other Change in Self-Reported Physical Activity Subjects will record their weekly physical activity using the Godin-Leisure Time Exercise Questionnaire (GLTEQ), measured by score. Scores less than 14 units are interpreted as insufficiently active/sedentary, while scores between 14 and 23 are interpreted as moderately active, and scores greater than 24 units are interpreted as active. From enrollment to end of treatment at 12 weeks, post-intervention at Week 16
Primary Change in Gait Speed The Timed 25-Foot Walk Test (T25FWT) to record duration of time to walk a distance of 25 feet, measured in seconds. The score is the average of two successive trials. Week 1, Week 6, Week 12
Primary Change in Perceived Walking Ability Multiple Sclerosis Walking Scale-12 (MSWS-12) to measure perceived impact of MS on walking ability, measured by score. Scores on the MSWS-12 range from 12-60 and transformed to a scale with a range from 0 to 100, with high scores indicative of a greater impact of MS on walking. Week 1, Week 6, Week 12
Primary Change in MS Disability Expanded Disability Status Scale (EDSS), administered by a trained clinician, to quantify disability in MS and monitor changes in the level of disability over time. The EDSS scale ranges from 0 to 10, with high scores indicative of higher levels of disability. Day 0, Week 6, Week 12
Primary Change in Fall Risk Berg Balance Scale (BBS) to assess balance in 14 tasks, measured by score. Scores of the BBS range from 0 to 56, with 0-20 being wheelchair bound, 21-40 being walking with assistance, and 41-56 classified as independent. Week 1, Week 6, Week 12
Primary Amount of Daily Walking/Activity Level Collected by the usage log of the device(s), measured in steps per day Day 0, from enrollment to end of treatment at 12 weeks, post-intervention at Week 16
Primary Duration of Daily Walking/Activity Level Collected by the usage log of the device(s), measured in duration of activity. Day 0, from enrollment to end of treatment at 12 weeks, post-intervention at Week 16
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4
Completed NCT02845635 - MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis